Controversy continues to surround deep sclerectomy

Article

Deep sclerectomy is not the holy grail of glaucoma surgery, but available evidence indicates that it is definitively safer than trabeculectomy and that it can result in long-term success rates matching those of trabeculectomy when performed with proper technique by experienced hands, said Tarek M. Shaarawy, MD, at the World Ophthalmology Congress.

Deep sclerectomy is not the holy grail of glaucoma surgery, but available evidence indicates that it is definitively safer than trabeculectomy and that it can result in long-term success rates matching those of trabeculectomy when performed with proper technique by experienced hands, said Tarek M. Shaarawy, MD, at the World Ophthalmology Congress.

Dr. Shaarawy acknowledged that the role of deep sclerectomy in glaucoma surgery is highly controversial and that it has its drawbacks. There is a long learning curve for the procedure, each case takes more time to perform than trabeculectomy, and it is a more costly procedure as well if an implant is used. However, all publications seem to agree it has a safety advantage compared with standard filtration surgery for reducing rates of hypotony, hyphema, choroidal detachment, and particularly, surgically induced cataract.

While the efficacy of deep sclerectomy may be questioned based on the results of some studies, Dr. Shaarawy pointed out that closer examination of those reports reveals the presence of certain factors that could be expected to negatively influence the outcomes. Those potential confounders include improper depth of dissection of the deep sclera and use of Nd:YAG goniopuncture to define treatment failure.

To demonstrate the potential efficacy of deep sclerectomy, Dr. Shaarawy presented the long-term results from his own series of 105 patients in which success, defined by an IOP of 15 mm Hg or lower without medication, was achieved in 49% of eyes after up to 8 years of follow-up. About half of the eyes in the study underwent goniopuncture postoperatively, and the surgery routinely incorporated placement of a collagen implant, which Dr. Shaarawy showed in other comparative trials improved outcomes relative to deep sclerectomy without an implant.

"Deep sclerectomy is far from perfect. However, I will leave it to the able and intelligent minds of those in the audience to decide based on this information whether the take-home message is that when compared with trabeculectomy, deep sclerectomy can achieve similar IOP control with significantly fewer complications," concluded Dr. Shaarawy of Geneva, Switzerland.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.